SCIG Therapy Is Cost-Saving Versus IVIG in Canadian Study of Primary Immunodeficiency Patients
This first-ever prospective economic analysis by Canadian investigators found that home-based subcutaneous immune globulin (SCIG) therapy was associated with significantly lower average total nondrug costs than hospital-based intravenous immune globulin (IVIG) therapy for patients with primary immunodeficiency disorders.
Mylan’s Ogivri Approved as Biosimilar to Herceptin
Mylan’s Ogivri (trastuzumab-dkst) has been approved by the U.S. Food and Drug Administration as a biosimilar to Genentech’s Herceptin (trastuzumab).
Subcutaneous Immune Globulin Effective as Maintenance Treatment in Chronic Inflammatory Demyelinating Polyneuropathy
A Phase III, placebo-controlled study demonstrated both low-dose and high-dose therapy with a licensed, self-administered subcutaneous immune globulin product was efficacious and well-tolerated as maintenance treatment for patients with chronic inflammatory demyelinating polyneuropathy.
CSL Behring ’s Privigen Now Approved to Treat CIDP
The U.S. Food and Drug Administration (FDA) has approved Privigen (immune globulin intravenous [human] 10% liquid) to treat adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability.
Expanding Uses of IVIG
Researchers are taking a closer look at intravenous immune globulin for its potential to stop the progression of multiple complex conditions from lupus to multiple sclerosis.
Subcutaneous Immunoglobulin Well-Tolerated and Effective in Mild to Moderate Exacerbations of Myasthenia Gravis
Canadian investigators at the University of Alberta evaluated the use of self-administered subcutaneous immune globulin in a prospective, open-label, Phase III crossover trial in adult patients with myasthenia gravis experiencing mild to moderate worsening of symptoms.
IVIG Highly Protective in Ferrets After Challenge with Severe Pandemic pH1N1 and Avian H5N1 Influenza Strains
Australian investigators tested the ability of intravenous immune globulin to protect against potential pandemic influenza virus in outbred ferrets, which are naturally susceptible to human influenza viruses and considered a relevant small animal model of human influenza infection.
Intravenous Immune Globulin Improves Systemic Sclerosis Symptoms
Administration of high-dose intravenous immune globulin (IVIG) significantly improved muscle and joint pain, muscle weakness and markers of systemic inflammation, according to a retrospective evaluation of 46 systemic sclerosis patients at 19 French centers.
IVIG Treatment May Lead to Poorer Outcomes in GBS Patients
A new study shows that individuals treated with intravenous immune globulin (IVIG) for Guillain-Barré syndrome are at increased risk of developing hypoalbuminemia (reduced albumin levels).
FDA Approves Gammaplex 10% to Treat Adult PI and ITP Patients
The U.S. Food and Drug Administration has approved Bio Products Laboratory’s Gammaplex 10% (immune globulin intravenous [human] 10% liquid) for the treatment of primary immunodeficiency (PI) and chronic immune thrombocytopenic purpura in adults.
